MediPharm Labs Reports Fourth Quarter and Full Year Results
Annual Revenue and Adjusted EBITDA Improve by 50%
TORONTO, March 27, 2024 /PRNewswire/ – MediPharm Labs Corp. (TSX:LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.
Related news for (MEDIF)
- MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
- Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
- MediPharm Labs’ Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident
- MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
- MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital